Table 2 List of 16 antitumor drugs that are more sensitive in high-risk patients and 4 antitumor agents with more sensitivity in patients with low risk
16 antitumor drugs that are more sensitive to patients in the high-risk group | |
 Antitumor drugs | Description |
 AKT inhibitor | AKT inhibitor |
 AZ628 | Raf inhibitor |
 BAY 61–3606 | Syk inhibitor |
 Embelin | IAP inhibitor |
 Epothilone.B | Macrolide antitumor factors |
 Gemcitabine | Gemcitabine |
 GSK-650394 | SGK inhibitor |
 Imatinib | tyrosine kinase inhibitor |
 Mitomycin C | Mitomycin C |
 MS-275 | Entinostat HDAC inhibitor |
 PAC-1 | Caspase activator |
 Pyrimethamine | Ethambutol |
 Roscovitine | CDK inhibitor |
 Salubrinal | eIF2α dephosphorylation inhibitor |
 Sorafenib | The serine/threonine kinase activities of RAF-1 and B-Raf and tyrosine kinase activities of VGFR-2, VEGF-3, PDGF-β, KIT and FLT-3 receptors were inhibited |
 Thapsigargin | Tunicamycin,endoplasmic reticulum stress inducer |
4 antitumor drugs that are more sensitive to patients in the low-risk group | |
 Antitumor drugs | Description |
 Erlotinib | HER1/EGFR tyrosine kinase inhibitor |
 Lapatinib | Lapatinib |
 WZ-1–84 | PARP inhibitor |
 Z-LLNle-CHO | γ-Secretase inhibitor I |